Free Trial
NASDAQ:ENSC

Ensysce Biosciences (ENSC) Stock Price, News & Analysis

Ensysce Biosciences logo
$2.31 +0.04 (+1.54%)
Closing price 07/3/2025 03:43 PM Eastern
Extended Trading
$2.31 0.00 (0.00%)
As of 07/3/2025 04:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Ensysce Biosciences Stock (NASDAQ:ENSC)

Key Stats

Today's Range
$2.25
$2.33
50-Day Range
$2.02
$3.05
52-Week Range
$1.62
$14.67
Volume
9,667 shs
Average Volume
949,859 shs
Market Capitalization
$5.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Ensysce Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
1st Percentile Overall Score

ENSC MarketRank™: 

Ensysce Biosciences scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Ensysce Biosciences.

  • Earnings Growth

    Earnings for Ensysce Biosciences are expected to decrease in the coming year, from ($8.33) to ($12.77) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Ensysce Biosciences is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Ensysce Biosciences is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Ensysce Biosciences has a P/B Ratio of 0.89. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Ensysce Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    13.42% of the float of Ensysce Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Ensysce Biosciences has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Ensysce Biosciences has recently increased by 199.18%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Ensysce Biosciences does not currently pay a dividend.

  • Dividend Growth

    Ensysce Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.42% of the float of Ensysce Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Ensysce Biosciences has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Ensysce Biosciences has recently increased by 199.18%, indicating that investor sentiment is decreasing significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Ensysce Biosciences this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Ensysce Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 7.90% of the stock of Ensysce Biosciences is held by insiders.

  • Percentage Held by Institutions

    Only 5.63% of the stock of Ensysce Biosciences is held by institutions.

  • Read more about Ensysce Biosciences' insider trading history.
Receive ENSC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ensysce Biosciences and its competitors with MarketBeat's FREE daily newsletter.

ENSC Stock News Headlines

Ensysce Biosciences (NASDAQ:ENSC) Stock Price Up 1.5% - Still a Buy?
A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
Ensysce Flat on Receiving Grant
Ensysce Biosciences secures patent for OUD treatment
Ensysce Biosciences receives U.S. patent for OUD treatment
See More Headlines

ENSC Stock Analysis - Frequently Asked Questions

Ensysce Biosciences' stock was trading at $8.14 at the beginning of the year. Since then, ENSC shares have decreased by 71.7% and is now trading at $2.3050.

Ensysce Biosciences, Inc. (NASDAQ:ENSC) released its earnings results on Tuesday, May, 13th. The company reported ($1.39) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($3.02) by $1.63. The business earned $1.32 million during the quarter, compared to analyst estimates of $0.65 million. Ensysce Biosciences had a negative net margin of 109.49% and a negative trailing twelve-month return on equity of 192.54%.

Ensysce Biosciences's stock reverse split on Friday, March 31st 2023.The 1-12 reverse split was announced on Friday, March 31st 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 31st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Shares of ENSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ensysce Biosciences investors own include Predictive Oncology (POAI), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT), Meta Platforms (META), Insulet (PODD) and Broadcom (AVGO).

Company Calendar

Last Earnings
5/13/2025
Today
7/06/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ENSC
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$7.99 million
Net Margins
-109.49%
Pretax Margin
-109.49%

Debt

Sales & Book Value

Annual Sales
$5.21 million
Price / Cash Flow
N/A
Book Value
$2.59 per share
Price / Book
0.89

Miscellaneous

Free Float
2,184,000
Market Cap
$5.46 million
Optionable
Not Optionable
Beta
0.98
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:ENSC) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners